Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLS SELLAS Life Sciences Group Inc
- Stocks
- Healthcare
- NASDAQ: SLS
Price (delayed)
$1.63
Market cap
$162.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$135.01M
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from
Highlights
SELLAS Life Sciences Group's equity has soared by 193% from the previous quarter and by 187% YoY
The quick ratio has soared by 182% from the previous quarter
SELLAS Life Sciences Group's debt has decreased by 13% QoQ but it has increased by 9% YoY
Key stats
What are the main financial stats of SLS
Market
Valuations
Earnings
Shares outstanding
99.78M
Market cap
$162.64M
Enterprise value
$135.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.33
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$27.93M
Net income
-$27.13M
EBIT
-$27.13M
EBITDA
-$26.56M
Free cash flow
-$33.71M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.38
Book value per share
$0.31
Revenue per share
$0
TBVPS
$0.38
Total assets
$34.96M
Total liabilities
$7.2M
Debt
$870,000
Equity
$27.76M
Working capital
$25.09M
Debt to equity
0.03
Current ratio
4.64
Quick ratio
4.14
Net debt/EBITDA
1.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-113%
Return on equity
-193.7%
Return on invested capital
N/A
Return on capital employed
-96.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLS stock price
How has the SELLAS Life Sciences Group stock price performed over time
Intraday
1.88%
1 week
4.49%
1 month
27.34%
1 year
10.88%
YTD
56.73%
QTD
50.93%
Financial performance
How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.93M
Net income
-$27.13M
Gross margin
N/A
Net margin
N/A
SELLAS Life Sciences Group's net income has increased by 24% YoY and by 12% QoQ
The operating income has grown by 23% YoY and by 11% from the previous quarter
Price vs fundamentals
How does SLS's price correlate with its fundamentals
Growth
What is SELLAS Life Sciences Group's growth rate over time
Valuation
What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
5.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS has surged by 65% year-on-year and by 24% since the previous quarter
SELLAS Life Sciences Group's equity has soared by 193% from the previous quarter and by 187% YoY
SLS's price to book (P/B) is 47% lower than its last 4 quarters average of 10.0 and 26% lower than its 5-year quarterly average of 7.2
Efficiency
How efficient is SELLAS Life Sciences Group business performance
The company's return on equity has surged by 96% YoY and by 40% QoQ
SELLAS Life Sciences Group's return on assets has surged by 55% YoY and by 22% QoQ
Dividends
What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLS.
Financial health
How did SELLAS Life Sciences Group financials performed over time
The quick ratio has soared by 182% from the previous quarter
SLS's current ratio has soared by 170% since the previous quarter
SELLAS Life Sciences Group's debt is 97% lower than its equity
SELLAS Life Sciences Group's equity has soared by 193% from the previous quarter and by 187% YoY
The debt to equity has plunged by 73% from the previous quarter and by 63% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.